Back to Search Start Over

Vertex Pharmaceuticals price target lowered by $10 at Oppenheimer, here's why

Source :
The Fly. October 30, 2024
Publication Year :
2024

Abstract

Oppenheimer lowered the firm's price target on Vertex Pharmaceuticals to $540 from $550 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating its [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
The Fly
Publication Type :
Periodical
Accession number :
edsgcl.814201126